AgenT-797 (MiNK Therapeutics), an allogeneic off-the-shelf invariant natural killer T-cell therapy was well-tolerated and improved survival inpatients with COVID-19-associated acute respiratory distress syndrome (ARDS) in addition to mechanical ventilation or ECMO.